Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TELO Stock Forecast 2026-2027
$1.24
Current Price
$85.28M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TELO Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
TELO Price Momentum
-2.4%
1 Week Change
+2.5%
1 Month Change
+6.0%
1 Year Change
-6.8%
Year-to-Date Change
-60.0%
From 52W High of $3.10
+18.1%
From 52W Low of $1.05
📊 TOP ANALYST CALLS
Did TELO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Telomir is one of their latest high-conviction picks.
Latest TELO Stock Price Targets & Analyst Predictions
TELO has shown a year-to-date change of -6.8% and a 1-year change of 6.0%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TELO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TELO Analyst Ratings
0
Buy
0
Hold
0
Sell
TELO Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.24
Latest TELO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TELO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Telomir Pharmaceuticals Inc. (TELO) Competitors
The following stocks are similar to Telomir based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Telomir Pharmaceuticals Inc. (TELO) Financial Data
Telomir Pharmaceuticals Inc. has a market capitalization of $85.28M with a P/E ratio of -3.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -384.3%.
Valuation Metrics
Market Cap
$85.28M
Enterprise Value
$80.27M
P/E Ratio
-3.7x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+6.5%
Current Ratio
7.0x
Debt/Equity
11.0x
ROE
-384.3%
ROA
-186.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Telomir Pharmaceuticals Inc. (TELO) Business Model
About Telomir Pharmaceuticals Inc.
What They Do
Develops innovative therapeutic solutions in oncology.
Business Model
The company focuses on research and development of advanced medicines, generating revenue through the development and commercialization of its drug candidates. It operates a pipeline of therapies at various clinical trial stages, emphasizing precision medicine, which allows for targeted treatment of diseases.
Additional Information
Telomir Pharmaceuticals Inc. collaborates with leading medical institutions and utilizes advanced biotechnology to enhance its drug development processes. As part of the biotechnology and pharmaceutical industry, it contributes significantly to healthcare innovations aimed at improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1
CEO
Mr. Erez Aminov
Country
United States
IPO Year
N/A
Website
telomirpharma.comTelomir Pharmaceuticals Inc. (TELO) Latest News & Analysis
Latest News
Quick Summary
Telomir Pharmaceuticals (NASDAQ: TELO) reported that Telomir-Zn treatment normalized insulin resistance and improved glucose metabolism in a preclinical model of Type 2 diabetes, supporting its therapeutic potential.
Why It Matters
Telomir-Zn's success in normalizing insulin resistance and improving glucose metabolism could signal a breakthrough in diabetes treatment, potentially boosting Telomir Pharmaceuticals' stock and market position.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) announced positive preclinical results for Telomir-Zn in a Wilson's disease model, showing improved survival, reduced copper burden, and better liver biomarkers.
Why It Matters
Positive preclinical results for Telomir's treatment could enhance its market position, attract investment, and indicate potential for future revenue, influencing stock performance for Telomir Pharmaceuticals.
Source: Accesswire
Market Sentiment:
Neutral
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
2 months ago
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) has received FDA clearance for its IND application for Telomir-Zn, with plans to start a Phase 1/2 trial in 1H 2026 for advanced triple-negative breast cancer.
Why It Matters
FDA clearance for Telomir-Zn positions Telomir Pharmaceuticals for potential breakthroughs in cancer treatment, attracting investor interest in its future growth and market prospects.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) has completed its acquisition of TELI Pharmaceuticals, securing global rights to its lead program and initial funding with milestone-based capital support.
Why It Matters
The acquisition enhances Telomir's asset portfolio and provides funding tied to clinical milestones, potentially driving future growth and increasing shareholder value.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) submitted an IND application for its lead candidate, Telomir-1, targeting advanced Triple-Negative Breast Cancer, showing preclinical efficacy and safety.
Why It Matters
Telomir's IND application signals potential market entry for a novel cancer therapy, which could drive stock value, influence investor sentiment, and attract interest in the biotech sector.
Source: Accesswire
Market Sentiment:
Neutral
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
4 months ago
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reported new data showing that Telomir-1 induces tumor cell death specifically in various subtypes of triple-negative breast cancer, confirming its mechanistic efficacy.
Why It Matters
The confirmation of targeted tumor cell mortality by Telomir-1 enhances its investment potential, indicating a promising approach in treating aggressive cancers like TNBC and attracting future funding.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About TELO Stock
What is Telomir Pharmaceuticals Inc.'s (TELO) stock forecast for 2027?
Analyst forecasts for Telomir Pharmaceuticals Inc. (TELO) are not currently available. The stock is trading at $1.24.
Is TELO stock a good investment in 2027?
Analyst ratings for TELO are not currently available. The stock is currently trading at $1.24. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TELO stock?
Price predictions from Wall Street analysts for TELO are not currently available. The stock is trading at $1.24.
What is Telomir Pharmaceuticals Inc.'s business model?
The company focuses on research and development of advanced medicines, generating revenue through the development and commercialization of its drug candidates. It operates a pipeline of therapies at various clinical trial stages, emphasizing precision medicine, which allows for targeted treatment of diseases.
What is the highest forecasted price for TELO Telomir Pharmaceuticals Inc.?
Price targets from Wall Street analysts for TELO are not currently available. The stock is trading at $1.24.
What is the lowest forecasted price for TELO Telomir Pharmaceuticals Inc.?
Price targets from Wall Street analysts for TELO are not currently available. The stock is trading at $1.24.
What is the overall TELO consensus from analysts for Telomir Pharmaceuticals Inc.?
Analyst ratings for TELO are not currently available. The stock is trading at $1.24.
How accurate are TELO stock price projections?
Stock price projections, including those for Telomir Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 12:47 PM UTC